الفهرس 
Introduction & Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
:Hepatocellular carcinoma (HCC) regards a major global health problem. It is counted as the fifth most common cancer and the second most common cause of cancer-related death worldwide. It is characterized by a high incidence and a poor clinical prognosis. Unfortunately, the delayed diagnosis, the limited treatment options, and the resistance to chemotherapeutic drugs are considered obstacles for HCC treatment. MiR-16 and miR-375 act as tumor suppressors by inhibiting malignant properties of cancer cells. It has been shown that miR-16 and miR-375 are down regulated in many tumor types and their down regulation often correlate with poor prognosis suggesting that miR-16 and miR-375 are capable of directly contributing to carcinogenesis. This study aimed to develop new effective treatment strategies that can be achieved by enhancing diagnosis accuracy and decreasing resistance to chemotherapeutic drugs to reduce mortality and improve survival rates. Therefore, the clinical value of using serum expression level of miR-16 and miR-375 as a diagnostic biomarker for HCC patients was investigated. Then, the potential outcome of combining natural products such as thymoquinone (TQ) and Epigallocatechin gallate (EGCG) with doxorubicin (DOX) on tumor growth in vitro was studied. Also, the mechanism of these natural products was investigated. MiR-16 and miR-375 are promising diagnostic marker for HCC as it correlates with total bilirubin. HCC treatment with DOX in combination with either TQ or EGCG induces a significant increase in miR-16 and miR-375 expression level and enhancement of cell death. TQ and EGCG potentiate the apoptotic effect of DOX in cancer cells.